To get the latest experience from our website, please upgrade your browser.
A study found people who lost weight with the Type 2 diabetes drug Invokana (canagliflozin) got hungrier and ate more, leading to a weight loss plateau. The study conducted by David Polidori and colleagues will publish in Obesity during Obesity [...]Read More
The U.S. Food and Drug Administration created a program that allows medical device makers to hide adverse events and report them years later, the Star Tribune reported. Doctors and patients [...]
After critics accused Johnson & Johnson and Bayer of hiding data in clinical trials for their blockbuster blood thinner Xarelto (rivaroxaban), the U.S. Food and Drug Administration said the drug [...]
Men who take testosterone supplements for cardiovascular, sexual and physical function probably won’t see any benefits, researchers report. Researchers at Georgetown University collected data that suggests testosterone replacement therapy has [...]
Johnson & Johnson’s Janssen Pharmaceuticals knew about a faulty device and data in a Xarelto (rivaroxaban) regulatory trial that suggests they put participants at risk, The BMJ reports. Janssen withheld [...]
Patients who suffered trauma and received inferior vena cava (IVC) filters to prevent blood clots in the lungs had no survival advantage, researchers reported. The study published in JAMA Surgery [...]